Home » Authors » Jim Shrine

Jim Shrine

Articles

ARTICLES

Cephalon Acquiring Approved Muscle Relaxant For $100M

Aug. 24, 2007

Cephalon Acquiring Approved Muscle Relaxant For $100M

Aug. 24, 2007

Nuvelo Restarts Testing With Higher Dose Of Alfimerprase

Aug. 23, 2007

Nuvelo Restarts Testing With Higher Dose Of Alfimerprase

Aug. 23, 2007

Oncoscience Starts Phase III Trials Of YM's Nimotuzumab

Aug. 22, 2007

Oncoscience Starts Phase III Trials Of YM's Nimotuzumab

Aug. 22, 2007

Insys Registers For IPO To Fund Cannabinoid, Fentanyl Products

Aug. 21, 2007

Insys Registers For IPO To Fund Cannabinoid, Fentanyl Products

Aug. 21, 2007

Cephalon Planning sNDA Filing Of Fentora In Breakthrough Pain

Aug. 17, 2007

Cephalon Planning sNDA Filing Of Fentora In Breakthrough Pain

Aug. 17, 2007

View All Articles by Jim Shrine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...